Improving and Expanding Access to Care and Treatments for COVID-19
Directs federal health and defense agencies to accelerate COVID-19 treatment development, boost healthcare system capacity, and improve affordability and access to care for all Americans, including the uninsured.
Establishes a coordinated multi-agency framework with the COVID-19 Response Coordinator at the center, requiring concrete plans and targets rather than making direct regulatory changes — most real-world impact depends on agency follow-through.
What this order does
What it orders
The order directs the Secretary of HHS, in consultation with the NIH Director, to develop plans for supporting large-scale clinical trials, identifying optimal COVID-19 treatment strategies, funding research in rural hospitals, and studying long-term patient health impacts. It directs the Secretaries of Defense, HHS, and Veterans Affairs to provide surge assistance to critical care and long-term care facilities, establish production and distribution targets for COVID-19 therapeutics, and — separately — identify barriers to equitable use of existing treatments. HHS is also directed to issue workforce capacity recommendations, expand access to community health centers, evaluate the COVID-19 Uninsured Program, and review Medicare and Medicaid coverage for COVID-19 treatments.
The order does not itself change any regulation, create any new benefit enforceable at law, or alter insurance coverage requirements. All significant outcomes depend on subsequent agency action, rulemaking, or appropriations. A standard severability clause states that nothing in the order may impair existing agency authority or OMB's budgetary functions.
Who it affects
Federal agencies including HHS, DoD, and VA; community health centers and safety-net providers; critical care, long-term care, and skilled nursing facilities; State and local health authorities; and, indirectly, uninsured and underinsured patients seeking COVID-19 treatment, rural communities, and historically underrepresented clinical-trial populations.
Why it matters
Uninsured patients, rural hospitals, long-term care residents, and underrepresented groups in clinical trials could see improved access to COVID-19 treatments if agencies act on the order's directives. The practical effect depends on whether agencies complete the required plans, evaluations, and distribution targets — and whether funding is available.
What must happen and when
How the order is supposed to work
The COVID-19 Response Coordinator serves as the central hub, with the Secretaries of Defense, HHS, and Veterans Affairs required to coordinate through that office for facility reviews, surge assistance, and distribution targets. HHS drives most individual action items, with HRSA and SAMHSA as implementing sub-agencies for community health access. The order carries no hard statutory deadlines — "promptly" is the operative timing word — and no enforcement mechanism; compliance depends on internal executive-branch accountability and budget availability.
Actions and deadlines
- Develop a plan for supporting large-scale clinical trials and identifying optimal COVID-19 treatment strategies
- Develop a plan supporting research in rural hospitals and on long-term COVID-19 health impacts
- Consider steps to ensure clinical trials include historically underrepresented populations
- Provide surge assistance to critical care and long-term care facilities combating COVID-19 spread
- Review needs of federal facilities caring for COVID-19 patients and develop recommendations for further action
- Issue recommendations on how states and providers can increase healthcare workforce capacity
- Expand access to programs for long-term COVID-19 patient recovery through community health centers
- Establish production, allocation, and distribution targets for COVID-19 treatments
- Identify barriers to equitable use of existing COVID-19 treatments and provide support to state and local authorities
- Evaluate the COVID-19 Uninsured Program and take steps to promote patient access to treatments
- Evaluate Medicare, Medicaid, and private insurance coverage for COVID-19 treatments and take steps to improve coverage